CN Patent

CN117586401A — 抗pd-1抗体及其用途

Assigned to Tayu Huaxia Biotech Medical Group Co ltd · Expires 2024-02-23 · 2y expired

What this patent protects

本申请提供抗PD‑1抗体或其片段。在各种实例中，所述抗体或其片段包含重链可变区和轻链可变区，所述重链可变区包含重链互补决定区HCDR1(SEQ ID NO:1、SEQ ID NO:7或SEQ ID NO:13)、HCDR2(SEQ ID NO:2、SEQ ID NO:8或SEQ ID NO:14)和HCDR3(SEQ ID NO:3、SEQ ID NO:9或SEQ ID NO:15)，所述轻链可变区包含轻链互补决定区LCDR1(SEQ ID NO:4、SEQ ID NO:10或SEQ ID NO:16)、LCDR2(SEQ ID NO:5、SEQ ID …

USPTO Abstract

本申请提供抗PD‑1抗体或其片段。在各种实例中，所述抗体或其片段包含重链可变区和轻链可变区，所述重链可变区包含重链互补决定区HCDR1(SEQ ID NO:1、SEQ ID NO:7或SEQ ID NO:13)、HCDR2(SEQ ID NO:2、SEQ ID NO:8或SEQ ID NO:14)和HCDR3(SEQ ID NO:3、SEQ ID NO:9或SEQ ID NO:15)，所述轻链可变区包含轻链互补决定区LCDR1(SEQ ID NO:4、SEQ ID NO:10或SEQ ID NO:16)、LCDR2(SEQ ID NO:5、SEQ ID NO:11或SEQ ID NO:17)和LCDR3(SEQ ID NO:6、SEQ ID NO:12或SEQ ID NO:18)。还提供了使用所述抗体或其片段来治疗和诊断诸如癌症、感染或免疫紊乱的疾病的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN117586401A
Jurisdiction
CN
Classification
—
Expires
2024-02-23
Drug substance claim
No
Drug product claim
No
Assignee
Tayu Huaxia Biotech Medical Group Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.